NEW YORK (GenomeWeb News) – Emergent Biosolutions has appointed former National Cancer Institute Director John Niederhuber to serve on its board of directors.
Niederhuber was director at NCI from 2005 to 2010, and he recently joined Inova Health System as executive VP and CEO of the Inova Institute for Translational Research and Personalized Medicine. He also still works as an adjunct investigator at NCI’s Center for Cancer Research.
Before joining NCI, Niederhuber was director of the University of Wisconsin Comprehensive Cancer Center and he was chair of the Department of Surgery at Stanford University.
The Institute for Systems Biology has named Joseph Nadeau to replace ISB co-founder Alan Aderem as director of research and academic affairs. Nadeau has been chair of the genetics department at Case Western Reserve School of Medicine since 2003. Nadeau’s work has involved using informatics to predict genetic interactions, and he led a group at Jackson Laboratory that built the Mouse Genome Database in the 1980s.
Caris Life Sciences said this week that Winston Lam has joined the Company as executive VP of business development and chief legal officer.
Lam recently was group VP and associate general counsel for Schering-Plough’s global pharmaceutical business, and he has 25 years of business development experience in the pharmaceutical and medical device industries.
The Queensland Institute of Medical Research has appointed Frank Gannon to serve as QIMR’s new director and CEO. Gannon currently is director-general of Science Foundation Ireland, and he will relocate from Dublin to Brisbane to take over the new post in January.
Gannon formerly was executive director of the European Molecular Biology Organization and a senior scientist at the European Molecular Biology Laboratory in Heidelberg, Germany.
“[Gannon] has significant experience in managing science, widespread ties with the international scientific community and a passion for scientific excellence,” QIMR council chair professor John Hay said in a statement.
San Francisco-based molecular diagnostics startup MLC Dx recently disclosed several company executives in an SEC filing.
Thomas Willis is the company’s president and CEO. Prior to that, he worked at Affymetrix, following the firm’s acquisition of ParAllele BioScience, a company he co-founded and where he served as CEO and later as CSO.
Malek Faham is the firm’s CSO. Previously, he was vice president of oncology technology research at Affymetrix, and before that, director of research at ParAllele, which he also co-founded.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.